Your session is about to expire
← Back to Search
Combination Immunotherapy for Small Cell Lung Cancer
Study Summary
This trial is testing a new cancer treatment in patients who have already received chemotherapy for small cell lung cancer.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I have not taken high doses of steroids or immunosuppressants for an autoimmune disease in the last 3 months.I have lung disease that causes symptoms or could affect lung-related side effects from treatment.I have not had major surgery or a serious injury in the last 4 weeks.I have a tumor that can be biopsied.I have extensive stage small cell lung cancer that got worse after treatment, including platinum-based therapy.I can take care of myself and am up and about more than half of my waking hours.I am not pregnant or breastfeeding.I do not have an active HIV, HBV, or HCV infection.I have brain metastases but am not on high-dose steroids and finished radiation at least 2 weeks ago.I have brain metastases but do not have symptoms, or my symptoms are managed.Your lab tests show damage to important organs within 14 days before starting the study treatment.I do not have any severe illnesses or social situations that would stop me from following the study's requirements.I haven't had any cancer treatment in the last 3 weeks.
- Group 1: Nivolumab and Ipilimumab
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Are investigators actively looking for new participants?
"The clinical trial, which was created on December 6th 2018, is not currently looking for new patients. Although this specific trial is unavailable, there are 2412 other medical trials that are still recruiting right now."
Are there any short-term or long-term dangers associated with this immunotherapy treatment?
"While there is some data indicating that the immunotherapy drug combination of ipilimumab and nivolumab is safe, as this is only a Phase 2 trial, more information is needed to support its efficacy. Consequently, it received a score of 2."
What other research has been conducted on the effectiveness of this immunotherapy drug combination?
"At this time, there are 796 clinical trials underway for the combination immunotherapy of ipilimumab and nivolumab. 86 of these studies have progressed to Phase 3 testing. The majority of these tests are happening in Pittsburgh, but there are 43299 other locations around the world where similar trials are taking place."
What are the most popular reasons that doctors prescribe Ipilimumab and Nivolumab together?
"Ipilimumab and Nivolumab administered together create an immunotherapy cocktail that has been used to treat patients who have undergone anti-angiogenic therapy in the past. Additionally, this treatment can be used for those suffering from malignant neoplasms, unresectable melanoma, and squamous cell carcinoma."
How many study participants are needed for this clinical trial?
"1616 other clinical trials for small cell lung cancer (sclc) and 796 studies for combination immunotherapy with ipilimumab and nivolumab are currently recruiting patients."
Other Trials to Consider
Popular Categories
Share this study with friends
Copy Link
Messenger